Design, synthesis, in-vitro, in-silico, DFT and POM studies of a novel family of sulfonamides as potent anti-triple-negative breast cancer agents.
ADMET
Anti-breast cancer agents
Breast cancer
Ethacrynic acid
Indazole-sulfonamides
Molecular docking
POM
Journal
Computational biology and chemistry
ISSN: 1476-928X
Titre abrégé: Comput Biol Chem
Pays: England
ID NLM: 101157394
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
01
07
2024
revised:
04
09
2024
accepted:
12
09
2024
medline:
22
9
2024
pubmed:
22
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
In this study, a new family of ethacrynic acid-sulfonamides and indazole-sulfonamides was synthesized and tested in vitro against MDA-MB-468 triple-negative breast cancer cells and PBMCs human peripheral blood mononuclear cells, using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. The aim of this research is to discover novel compounds with potential therapeutic effects on breast cancer. The antiproliferative activity of these compounds showed a significant dose-dependent activity, with IC
Identifiants
pubmed: 39305691
pii: S1476-9271(24)00202-0
doi: 10.1016/j.compbiolchem.2024.108214
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108214Informations de copyright
Copyright © 2024 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:EL KAZZOULI Said reports was provided by Euro-Mediterranean University of Fes Euromed Research Center. EL KAZZOULI Said reports a relationship with Euro-Mediterranean University of Fes Euromed Research Center that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.